Review Article

New Allogeneic Hematopoietic Stem Cell Transplantation Method: Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation for Intractable Diseases

Naoki Hosaka¹,²

¹ Department of Pathology, Kansai Medical University Kori Hospital, 8-45 Korihondori, Neyagawa, Osaka 572-8851, Japan
² Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata City, Osaka 573-1010, Japan

Correspondence should be addressed to Naoki Hosaka; hosakan@takii.kmu.ac.jp

Received 9 January 2013; Revised 17 March 2013; Accepted 19 April 2013

Academic Editor: Margaret G. Petroff

Copyright © 2013 Naoki Hosaka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a valuable strategy for some intractable diseases, a number of problems remain to be resolved. We have developed a new HSCT method, HSCT + thymus transplantation (TT) from the same donor, which induces elevated T cell function with mild graft-versus-host disease (GVHD) in comparison to conventional HSCT alone and HSCT + donor lymphocyte infusion (HSCT + DLI). This new method is effective in the treatment of several intractable diseases and conditions, such as autoimmune diseases in aging, advanced malignant tumors, exposure to supralethal irradiation, multiple organ transplantation from different donors, and type 2 diabetes mellitus, for which conventional methods are ineffective. Our findings suggest that allo-HSCT + TT is preferable to conventional allo-HSCT alone or allo-HSCT + DLI. This method may become a valuable next-generation HSCT technique.

1. Introduction

In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a valuable strategy for the treatment of hematological disorders (leukemia, lymphoma, and aplastic anemia), congenital immunodeficiencies, autoimmune diseases, metabolic diseases, and malignant tumors [1–7]. However, there are still a number of problems associated with these methods. Although T cells in the graft facilitate engraftment, they often induce graft-versus-host disease (GVHD) [8]. Conversely, if the antithost reaction is low, hematopoietic failure and/or primary disease recurrence may occur. In addition, the success rate of hematopoietic stem cell transplantation (HSCT) is low in elderly patients with low facility for engraftment and/or risk of severe complications [9–11]. Recent experience with radiation accidents also indicated that HSCT alone is ineffective for patients exposed to supralethal doses of irradiation with severe organ damage [12, 13]. Therefore, it is extremely important to overcome these problems of allo-HSCT.

The thymus is the organ in which T cells are differentiated and produced with induction of tolerance to the host. The thymus also regulates biological homeostasis using the cells with several cytokines and hormones [14]. Therefore, allo-HSCT with cotransplantation of the thymus from the same donor may be a beneficial method, as another site of allo-T cell production. Thymus transplantation (TT) itself has been used to treat immunodeficiency diseases, such as DiGeorge syndrome and HIV infection, and to increase T cell function [15, 16]. TT is also effective in age-related diseases with correction of immune dysfunctions in mice [17]. To our knowledge, however, there have been no previous studies regarding the efficacy of HSCT + TT in treatment of intractable diseases.

We recently developed a method of allo-HSCT in conjunction with TT from the same donor [18–27]. This method results in elevated T cell function with mild GVHD compared to HSCT alone or HSCT + donor lymphocyte infusion (HSCT + DLI) [18]. The mechanism underlying these effects involves not only CD4⁺ FoxP3⁻ effector T cells (Teff cells) but also CD4⁺ FoxP3⁺ regulatory T cells (Treg cells), which
prevent GVHD and autoimmunity [28, 29], produced by the allotransplanted thymus. The percentages of these cells are intermediate between HSCT alone and HSCT + DLI. The percentage of T eff cells in HSCT + TT is lower than that in HSCT alone, but higher than that in HSCT + DLI, while the opposite is true for the percentage of T reg cells [18]. We have examined application of this method for several intractable diseases. Our findings indicated that allo-HSCT + TT is preferable to the conventional allo-HSCT alone or allo-HSCT + DLI for several intractable diseases and conditions.

2. Results

2.1. Theory of Allo-HSCT + TT. First, we present the theory of allo-HSCT + TT (Figure 1). In the case of conventional allo-HSCT, allo-HSC is transferred into the host, and allo-T cells develop in the host thymus. The T cells show induced tolerance toward the host with thymic antigen-presenting cells and/or epithelial cells [30] and do not induce GVHD with normal T cell function (Figure 1, left). In contrast, non-tolerant allo-T cells are externally supplied in the case of HSCT + DLI, resulting in strong GVHD, and the T cell number and function finally decrease (Figure 1, right). In the case of HSCT + TT, allo-T cells develop internally from the transplanted allo-thymus in the host. Interestingly, the T cells are partially tolerant to the host and induce low GVHD. In addition, the T cell function increases.

2.2. Application of Allo-HSCT + TT

2.2.1. Autoimmune Diseases. We examined the effects of HSCT + TT in treatment of several intractable diseases (Table 1). Female MRL/lpr mice develop systemic lupus erythematosus- (SLE-) like lupus glomerular nephritis [31]. Bone marrow transplantation (BMT) alone is ineffective in these mice because of the radioresistance with Fas deficiency [32–34]. However, BMT + adult thymus transplantation (ATT) overcame these problems and induced donor-derived chimerism [19]. As a result, also led to successful treatment of nephritis with reduction of serum autoantibodies and deposition of IgG in glomeruli. Aged female MRL/+ mice developed chronic pancreatitis with sialoadenitis [35]. HSCT (BMT or fetal liver cell transplantation (FLT)) is ineffective because of insufficient engraftment of donor cells with the involved host thymus (described below). However, HSCT (BMT or FLT) + fetal thymus transplantation (FTT) showed complete engraftment of donor cells and was effective in treating diseases with reduction of serum amylase [20]. These results suggest that these autoimmune diseases can be treated by replacement of the pathological hematopoietic system with HSCT + TT [36, 37].

2.2.2. Malignant Tumors. We next investigated the effects of HSCT + TT in tumor-bearing mice [18]. Mice treated with BMT alone showed significant tumor regression compared with untreated controls. Although mice treated with BMT + DLI showed greater tumor regression than those treated with BMT alone, strong GVHD also occurred and they died at an early stage. Interestingly, mice treated with BMT + ATT showed less GVHD than those treated with BMT + DLI, even with a comparable level of tumor regression.

We also examined the effects of HSCT + TT on leukemia [22]. In contrast to solid tumors, most mice treated with BMT + ATT or BMT + DLI showed almost complete remission of the tumor with long-term survival compared to those treated with BMT alone. However, the level of GVHD in those treated with BMT + ATT was significantly lower than that in those treated with BMT + DLI. These results suggest that BMT + ATT may be effective in treatment of not only solid tumors but also leukemia, without increased risk of GVHD.

The thymus atrophies with bone marrow suppression in hosts with advanced tumors, thus causing immunodeficiency, which is one of the major causes of death in such cases [38, 39]. We further examined the effects of HSCT + TT in mice bearing advanced tumors [21]. Although the thymus still atrophied in mice treated with allo-BMT + FTT, the transplanted fetal thymus had grown well. These mice showed longer-term survival than those treated with syngeneic-(syn-) or allo-BMT alone, or syn-BMT + FTT with inhibition of lung metastasis. Interestingly, third-party FTT was also effective (described below as triple chimera). These findings suggest that HSCT + TT may also be effective for long-term survival in advanced tumors.

2.2.3. Aging. Advanced age is one of the risk factors for unsuccessful BMT [9, 10]. The major reason for this is the thymic involution leading to insufficient T cell production and function, as described above. We examined the effects of BMT + FTT in aged models: senescence-accelerated mouse P1 strain (SAMP1) [40] and aged MRL/+ mice (same model as no. I) [20, 23]. Both strains of mice treated with HSCT + TT showed significantly longer survival than those treated with HSCT alone. Although donor cells could not be engrafted into the host by BMT alone, resulting in hematopoietic failure and early death, the cells could be engrafted sufficiently by BMT + FTT. Interestingly, these hosts with long-term survival also showed elevated T cell function compared to either untreated mice or those treated with HSCT alone, and the level was comparable to that in normal mice. These results suggest that BMT + FTT is effective not only for engraftment of donor cells but also in restoring immune function in aged hosts.

2.2.4. Use of Third-Party Thymus Tissue. Transplantation of multiple organs from different donors is desirable in patients with several intractable diseases. Although grafting of the thymus itself can also induce tolerance [41], its effects on further tolerance at allo-HSCT have not been examined. Therefore, we examined triple chimeras consisting of lethally irradiated athymic (nu/nu) (X) mice transplanted with allo-BMC (Y) and third-party fetal thymus (Z) with a different major histocompatibility complex (MHC) type from both BMC and host type (Figure 2). The mice showed tolerance to all three MHC types—host, BMC, and the grafted thymus—but not to a fourth foreign MHC type [23]. We further examined the triple chimera with the above aged mouse.
| Disease | Mouse model | TT | Results | Reference |
|---------|-------------|----|---------|-----------|
| (1) Autoimmune diseases | | | | |
| (i) Lupus-like glomerulonephritis | MRL/lpr | ATT | Treatment of the glomerulonephritis | [19] |
| (ii) Chronic pancreatitis | MRL/+ | FTT | Treatment of the chronic pancreatitis and sialoadenitis | [20] |
| (2) Malignant tumor | | | | |
| (i) Early tumor | BALB/c with Meth-A sarcoma | ATT | Regression of tumor with low GVHD | [18] |
| (ii) Advanced tumor | BALB/c with Meth-A sarcoma | FTT | Long-term survival with inhibition of lung metastasis | [21] |
| (iii) Leukemia | B6 with EL-4 leukemia | ATT | Remission of tumor with low GVHD | [22] |
| (3) Aging | MRL/+ | FTT | Long survival with elevation of T cell function | [20] |
| (4) Use of third-party thymus tissue | SAMP 1 | FTT | Same as above | [23] |
| (5) HSCT conditioning | B6, BALB/c, C3H (triple chimera) | FTT | Tolerance for 3 types of MHCs | [23] |
| (6) Type 2 diabetes mellitus | | | | |
| | db/db | NTT > FTT > ATT | Rescue with improvement of intestinal injury | [25] |

HSCT: hematopoietic stem cell transplantation; TT: thymus transplantation; ATT: adult thymus transplantation; NTT: newborn thymus transplantation; FTT: fetal thymus transplantation.
Figure 1: Theory of allo-HSCT + TT. In the case of conventional allo-HSCT (left), the allo-T cells develop and are tolerated in the host thymus, and no GVHD occurs. In the case of allo-HSCT + DLI (right), nontolerated allo-T cells are externally supplied, and strong GVHD is induced with reduction of T cell function. In the case of allo-HSCT + TT, the allo-T cells develop internally in the allothymus. The T cells show partial tolerance to the host, and only mild GVHD occurs with elevation of T cell function (middle).

Figure 2: Use of third-party thymus tissue in triple chimera. Lethally irradiated athymic nu/nu mice (host: X) were transplanted with allogenic HSC (donor: Y) and third-party thymus (donor: Z) as triple chimeras.

model, SAMP1 mice, and the same results of tolerance for three MHC types were obtained. Although this model is limited to hosts with low thymic function, these results suggest that HSCT + TT can also be applied for multiple organ transplantation from different donors using third-party TT.

2.2.5. HSCT Conditioning. Reduction of the intensity of the HSCT conditioning regimen will decrease the side effects for both host and donor. Therefore, we examined the effects of HSCT and TT for two conditions, that is, low-dose irradiation (sublethal irradiation (SubLI)), which attenuates host damage, and low numbers of BMC (injection of low numbers of BMC (ILNBM)), which reduces the burden on the donor [24]. BMT + DLI showed the shortest survival due to severe GVHD under both conditions, and BMT alone also showed short survival due to hematological failure in ILNBM. However, BMT + ATT was preferable for long-term survival with reduction of GVHD to BMT + DLI or with donor-derived chimeraism to BMT alone. Next, we investigated the effects of HSCT and TT on supralethal radiation exposure [25]. HSCT alone, such as BMT, newborn liver cell transplantation (NLT), or FLT, was almost completely ineffective in mice exposed to supralethal irradiation with severe intestinal injury and weight loss, as reported in humans [12, 13]. However, NLT + newborn thymus transplantation (NTT) rescued the animals with the greatest efficacy showing improvement of the injury and prevention of weight loss among the three types of HSCT + TT (BMT + ATT, NLT + NTT, and FLT + FTT).

2.2.6. Type 2 Diabetes Mellitus. There is increasing evidence that both autoimmune and autoinflammatory mechanisms are involved in the development of not only type 1 diabetes mellitus (T1 DM) but also type 2 DM (T2 DM) [42, 43]. Therefore, we recently examined the effects of HSCT + TT in leptin receptor-deficient (db/db) mice, an animal model of T2 DM [44]. BMT + NTT could be used to treat diabetes with complete replacement of HSC showing normalized immune functions, although BMT alone showed insufficient treatment with incomplete replacement of HSC and dysregulated immune function [26]. These results suggest that BMT + NTT may be effective for treatment of T2 DM and that correction of the pathogenic immunological function is important for treatment.

3. Discussion

As described above, allo-HSCT + TT is functionally superior to either conventional HSCT alone or HSCT + DLI for several intractable diseases and conditions. Elevation of T
cell function with low GVHD facilitates engraftment of donor cells in HSCT + TT, and these allo-T cells may work more effectively and safely in treatment of several diseases compared to HSCT alone or HSCT + DLI.

The elevation of T cell function in HSCT + TT is due to the newly developed T cells from the transplanted thymus [18]. In addition, the low GVHD is due to the partial deletion and induction of host antigen-reactive T\textsubscript{eff} and T\textsubscript{reg} cells from the transplanted allo-thymus. Although the detailed mechanism is not yet clear, it suggests that thymic antigen-presenting cells such as dendritic cells (DC) and/or medullary thymic epithelial cells (mTEC) in the transplanted thymus may play important roles with the antigen [30, 45–49] (Figure 3). As these T cells develop continuously in vivo, they do not induce lethal “autoimmune-like” GVHD to maintain homeostasis [50, 51]. Therefore, TT initially appears to represent a simple method but may represent a significant approach to supplying the organ in which T cells are differentiated, produced, and functionally regulated.

As the thymus shows functional differences with age, we also compared the effects of the thymus at three different ages (adult, newborn, and fetus) [25, 27]. Although HSCT + TT was superior to HSCT alone at all ages, NLT + NTT showed better results than FLC + FTT and BMT + ATT in these experiments. Although further studies are needed, these findings suggest that young thymus, as close as possible to newborn, may be preferable.

However, it is both ethically and technically difficult to obtain adequate thymus tissue for clinical use. In this respect, grafts could be obtained from patients with congenital heart diseases or from aborted fetuses, as utilized previously [15, 16]. These materials are close to the preferred NT and may be used in third-party TT. In addition, a method for thymus regeneration and differentiation from stem cells has also been developed [52–57]. Therefore, HSCT + TT may become a viable strategy for the treatment of intractable diseases, conditions, or transplantation, and therefore this may become a valuable next-generation HSCT method.

4. Conclusion

The findings presented here indicate that allo-HSCT + TT is more effective against several intractable diseases compared with conventional allo-HSCT methods. This method may become a valuable strategy for the treatment of various diseases in humans.

**Abbreviations**

Allo-HSCT: Allogeneic hematopoietic stem cell transplantation
ATT: Adult thymus transplantation
BMT: Bone marrow transplantation
DLI: Donor lymphocyte infusion
FTT: Fetal thymus transplantation
GVHD: Graft-versus-host disease
HSCT: Hematopoietic stem cell transplantation
NLT: Newborn liver cell transplantation
NTT: Newborn thymus transplantation
T\textsubscript{eff} cells: Effector T cells
T\textsubscript{reg} cells: Regulatory T cells
TT: Thymus transplantation
mTEC: Medullary thymic epithelial cells
DC: Dendritic cells.
Acknowledgments

The author wishes to thank Professor S. Ikehara of the Department of Stem Cell Disorders and Professor H. Takahashi of the Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, for support in this work.

References

[1] E. D. Thomas, “Landmarks in the development of hematopoietic cell transplantation,” World Journal of Surgery, vol. 24, no. 7, pp. 815–818, 2000.

[2] A. Bacigalupo, R. Oneto, B. Bruno et al., “Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation,” Acta Haematologica, vol. 103, pp. 19–25, 2000.

[3] R. L. Chen, J. W. Hou, P. Y. Chang, F. J. Tsai, and P. J. Wang, “Matched unrelated bone marrow transplantation without splenectomy for a child with Gaucher disease caused by homozygosity of the L444P mutation, who also suffered from schizencephaly,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 1, pp. 57–59, 2007.

[4] T. Sato, R. Kobayashi, N. Toita et al., “Stem cell transplantation in primary immunodeficiency disease patients,” Journal of Pediatric Hematology/Oncology, vol. 29, pp. 57–59, 2007.

[5] H. Kanamori, M. Tanaka, H. Kawaguchi et al., “Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature,” American Journal of Hematology, vol. 71, no. 1, pp. 41–44, 2002.

[6] N. Saba and T. Flag, “Bone marrow transplantation for non-malignant diseases,” Journal of Hemotherapy and Stem Cell Research, vol. 11, no. 2, pp. 377–387, 2002.

[7] N. T. Ueno, J. D. Rizzo, T. Demirer et al., “Allogeneic hematopoietic cell transplantation for metastatic breast cancer,” Bone Marrow Transplantation, vol. 41, no. 6, pp. 537–543, 2008.

[8] N. J. Chao, “Graft-versus-host disease: the viewpoint from the donor T cell,” Biology of Blood and Marrow Transplantation, vol. 3, no. 1, pp. 1–10, 1997.

[9] H. G. Klingemann, R. Storb, and A. Fefer, “Bone marrow transplantation in patients aged 45 years and older,” Blood, vol. 67, no. 3, pp. 770–776, 1986.

[10] O. Ringdén, T. Paulin, B. Lönnqvist, and B. Nilsson, “An analysis of factors predisposing to chronic graft-versus-host disease,” Experimental Hematology, vol. 13, pp. 1062–1067, 1985.

[11] R. S. Weiner, M. M. Bortin, and R. P. Gale, “Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors,” Annals of Internal Medicine, vol. 104, no. 2, pp. 168–175, 1986.

[12] H. Nagayama, J. Ooi, A. Tomonari et al., “Severe immune dysfunction after lethal neutron irradiation in a JCO nuclear facility accident victim,” International Journal of Hematology, vol. 76, no. 2, pp. 157–164, 2002.

[13] H. Nagayama, K. Misawa, H. Tanaka et al., “Transient hematopoietic stem cell rescue using umbilical cord blood for a lethally irradiated nuclear accident victim,” Bone Marrow Transplantation, vol. 29, no. 3, pp. 197–204, 2002.

[14] E. Arzt, D. Kovalovsky, L. Müller Igaz et al., “Functional cross-talk among cytokines, T-cell receptor, and glucocorticoid receptor transcriptional activity and action,” Annals of the New York Academy of Sciences, vol. 917, pp. 672–677, 2000.

[15] M. L. Markert, A. Boeck, L. P. Hale et al., “Transplantation of thymus tissue in complete DiGeorge syndrome,” New England Journal of Medicine, vol. 341, no. 16, pp. 1180–1189, 1999.

[16] M. L. Markert, C. B. Hicks, J. A. Bartlett et al., “Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection,” AIDS Research and Human Retroviruses, vol. 16, no. 5, pp. 403–413, 2000.

[17] H. Ivai and M. Inaba, “Fetal thymus graft prevents age-related hearing loss and up regulation of the IL-1 receptor type II gene in CD4+ T cells,” Journal of Neuroimmunology, vol. 250, pp. 1–8, 2012.

[18] T. Miyake, N. Hosaka, W. Cui et al., “Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects,” Immunology, vol. 126, no. 4, pp. 552–564, 2009.

[19] N. Hosaka, T. Ryu, T. Miyake et al., “Treatment of autoimmune diseases in MRL/lpr mice by allogenic bone marrow transplantation plus adult thymus transplantation,” Clinical and Experimental Immunology, vol. 147, no. 3, pp. 555–563, 2007.

[20] N. Hosaka, M. Nose, M. Kyogoku et al., “Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+ mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8558–8562, 1996.

[21] N. Hosaka, W. Cui, Y. Zhang, T. Takaki, M. Inaba, and S. Ikehara, “Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation,” Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1121–1130, 2010.

[22] Y. Zhang, N. Hosaka, Y. Cui, M. Shi, M. Li, Q. Li et al., “Effects of intrabone marrow-bone marrow transplantation plus adult thymus transplantation on survival of mice bearing leukemia,” Stem Cells and Development, vol. 21, pp. 1441–1448, 2012.

[23] W. Cui, N. Hosaka, T. Miyake et al., “Analysis of tolerance induction using triple chimeric mice: major histocompatibility complex-disparate thymus, hematopoietic cells, and microenvironment,” Transplantation, vol. 85, no. 8, pp. 1151–1158, 2008.

[24] T. Nishida, Y. Cui, H. Ikehara, T. Takaki et al., “Allogenic intra-BM-BMT plus adult thymus transplantation from same donor has benefits for long-term survival even after sublethal irradiation or low-dose BM cell injection,” Bone Marrow Transplantation, vol. 43, no. 11, pp. 829–837, 2009.

[25] T. Ryu, N. Hosaka, T. Miyake et al., “Transplantation of newborn thymus plus hematopoietic stem cells can rescue supralethally irradiated mice,” Bone Marrow Transplantation, vol. 41, no. 7, pp. 659–666, 2008.

[26] W. Li, N. G. Abraham, L. Vanella et al., “Successful modulation of type 2 diabetes in db/db mice with intra-bone marrow-bone marrow transplantation plus concurrent thymic transplantation,” Journal of Autoimmunity, vol. 35, no. 4, pp. 414–423, 2010.
[28] P. Hoffmann, J. Ermann, M. Edinger, C. Garrison Fathman, and S. Strober, “Donor-type CD4+ CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation,” Journal of Experimental Medicine, vol. 196, no. 3, pp. 389–399, 2002.

[29] S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012.

[30] A. K. Abbas, A. H. Lichtman, and S. Pillai, “Lymphocyte development the rearrangement and expression of antigen receptor genes,” in Maturation of T Lymphocytes, W. Schmitt and R. Grulow, Eds., pp. 175–188, Saunders Elsevier, Philadelphia, Pa, USA, 6th edition, 2009.

[31] B. Andrews, R. A. Eisenberg, and A. N. Theofilopoulos, “Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains,” Journal of Experimental Medicine, vol. 148, no. 5, pp. 1198–1215, 1978.

[32] R. Watanabe-Fukunaga, C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata, “Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis,” Nature, vol. 356, no. 6367, pp. 314–317, 1992.

[33] E. A. Reap, K. Roof, K. Maynor, M. Borrero, J. Booker, and P. L. Cohen, “Radiation and stress-induced apoptosis: a role for fas/fas ligand interactions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5750–5755, 1997.

[34] J. K. Booker, E. A. Reap, and P. L. Cohen, “Expression and function of Fas on cells damaged by γ-irradiation in B6 and B6/lpr mice,” Journal of Immunology, vol. 161, no. 9, pp. 4536–4541, 1998.

[35] H. Kanno, M. Nose, J. Itoh, Y. Taniguchi, and M. Kyogoku, “Spontaneous development of pancreatitis in the MRL/Mp strain of mice in autoimmune mechanism,” Clinical and Experimental Immunology, vol. 89, no. 1, pp. 68–73, 1992.

[36] S. Ikehara, “Bone marrow transplantation for autoimmune diseases,” Acta Haematologica, vol. 99, no. 3, pp. 116–132, 1998.

[37] S. Ikehara, “Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment,” International Journal of Molecular Medicine, vol. 1, no. 1, pp. 5–16, 1998.

[38] T. Toge, M. Oride, E. Yanagawa, S. Hamamoto, H. Kohno, K. Nakanishi et al., “Prognostic significance of lymphocyte proliferative responses to mitogens in gastric cancer patients,” in Japanese Journal of Surgery, vol. 12, pp. 424–428, 1982.

[39] D. Mandal, A. Bhattacharyya, L. Lahiry, T. Choudhuri, G. Sa, and T. Das, “Failure in peripheral immuno-surveillance due to thymic atrophy: importance of thymocyte maturation and apoptosis in adult tumor-bearer,” Life Sciences, vol. 77, no. 21, pp. 2703–2716, 2005.

[40] T. Takeda, M. Hosokawa, and S. Takeshita, “A new murine model of accelerated senescence,” Mechanisms of Ageing and Development, vol. 17, no. 2, pp. 183–194, 1981.

[41] I. K. Chinn and M. L. Markert, “Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly,” Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp. 1351–1355, 2011.

[42] J. P. Després and J. Lemieux, “Abdominal obesity and metabolic syndrome,” Nature, vol. 444, no. 7121, pp. 881–887, 2006.

[43] T. Suganami, J. Nishida, and Y. Ogawa, “A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2062–2068, 2005.

[44] R. L. Leibel, W. K. Chung, and S. C. Chua, “The molecular genetics of rodent single gene obesities,” Journal of Biological Chemistry, vol. 272, no. 51, pp. 31937–31940, 1997.

[45] G. Marodon, S. Fisson, B. Levacher, M. Fabre, B. L. Salomon, and D. Klatzmann, “Induction of antigen-specific tolerance by intrathymic injection of lentiviral vectors,” Blood, vol. 108, no. 9, pp. 2972–2978, 2006.

[46] G. Gottrand, K. Taleb, I. Ragon, A. S. Bergot, J. D. Goldstein, and G. Marodon, “Intrathymic injection of lentiviral vector curtails the immune response in the periphery of normal mice,” in Journal of Gene Medicine, vol. 14, pp. 90–99, 2012.

[47] N. Watanabe, Y. H. Wang, H. K. Lee et al., “Hassall’s corpuscles instruct dendritic cells to induce CD4+ CD25+ regulatory T cells in human thymus,” Nature, vol. 436, no. 7054, pp. 1181–1185, 2005.

[48] K. Aschenbrenner, L. M. D’Cruz, E. H. Vollmann et al., “Selection of Foxp3 regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells,” Nature Immunology, vol. 8, no. 4, pp. 351–358, 2007.

[49] A. Coutinho, I. Caramalho, E. Seixas, and J. Demengeot, “Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection,” Current Topics in Microbiology and Immunology, vol. 293, pp. 43–71, 2005.

[50] S. Sakaguchi, M. Ono, R. Setoguchi et al., “Foxp3+ CD4+ regulatory T cells in dominant self-tolerance and autoimmune disease,” Immunological Reviews, vol. 212, pp. 8–27, 2006.

[51] H. Bour-Jordan and J. A. Bluestone, “Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells,” Immunological Reviews, vol. 229, no. 1, pp. 41–66, 2009.

[52] L. Zhang, L. Sun, and Y. Zhao, “Thymic epithelial progenitor cells and thymus regeneration: an update,” Cell Research, vol. 17, no. 1, pp. 50–55, 2007.

[53] L. Lai and J. Jin, “Generation of thymic epithelial cell progenitors by mouse embryonic stem cells,” Stem Cells, vol. 27, no. 12, pp. 3012–3020, 2009.

[54] T. Takagi, N. Hosaka, T. Miyake et al., “Presence of donor-derived thymic epithelial cells in [B6→MLR/lpr] mice after allogeneic intra-bone marrow-bone marrow transplantation (IBM-BMT),” Journal of Autoimmunity, vol. 31, no. 4, pp. 408–415, 2008.

[55] S. W. Rossi, W. E. Jenkinson, G. Anderson, and E. J. Jenkinson, “Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium,” Nature, vol. 441, no. 7096, pp. 988–991, 2006.

[56] L. Lai, C. Cui, J. Jin, Z. Hao, Q. Zheng, M. Ying et al., “Mouse embryonic stem cell-derived thymic epithelial cell progenitors enhance T-cell reconstitution after allogeneic bone marrow transplantation,” in Blood, vol. 118, pp. 3410–3418, 2011.

[57] A. Isotani, H. Hatayama, K. Kaseda, M. Ikawa, and M. Okabe, “Formation of a thymus from rat ES cells in xenogeneic nude mouse→rat ES chimeras,” Genes to Cells, vol. 16, no. 4, pp. 397–405, 2011.